Sequential intravenous/oral moxifloxacin versus intravenous piperacillin-tazobactam followed by oral amoxicillin-clavulanate for the treatment of complicated skin and skin structure infection

International Journal of Antimicrobial Agents

Volumn 26, Issue 5, 2005, Pages 357-365

  Giordano, Philip ^a,c   Song, James ^b   Pertel, Peter ^b   Herrington, Janet ^b   Kowalsky, Steven ^b  

^a ORLANDO REGIONAL MEDICAL CENTER   (United States)

^b BAYER CORPORATION   (United States)

^c Department of Emergency Medicine ^*  (United States)

Author keywords

Complicated skin and skin structure infections; Efficacy; Moxifloxacin; Piperacillin tazobactam; Safety

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; MOXIFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM;

ABSCESS; ADULT; AGED; ALLERGIC REACTION; CARDIOPULMONARY ARREST; CELLULITIS; CLINICAL TRIAL; CONFERENCE PAPER; CONFIDENCE INTERVAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; FEMALE; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE WEAKNESS; NAUSEA; OSTEOMYELITIS; PRIORITY JOURNAL; PSEUDOMEMBRANOUS COLITIS; RANDOMIZED CONTROLLED TRIAL; RASH; SKIN INFECTION; SKIN STRUCTURE; SKIN ULCER; STAPHYLOCOCCUS AUREUS;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION; ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, BACTERIAL; DRUG TOLERANCE; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; PENICILLANIC ACID; PIPERACILLIN; PROSPECTIVE STUDIES; QUINOLINES; SAFETY; SKIN DISEASES, BACTERIAL;

EID: 26944451676     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2005.07.017     Document Type: Conference Paper

References (36)

1. HG. Deery 2nd. Outpatient parenteral anti-infective therapy for skin and soft-tissue infections Infect Dis Clin North Am 12 1998 935 949
2. R.L. Nichols, and S. Florman Clinical presentations of soft-tissue infections and surgical site infections Clin Infect Dis 33 Suppl. 2001 84 93
3. R.L. Nichols Optimal treatment of complicated skin and skin structure infections J Antimicrob Chemother 44 1999 19 23
4. G.V. Doern, R.N. Jones, M.A. Pfaller, K.C. Kugler, and M.L. Beach Bacterial pathogens isolated from patients with skin and soft tissue infections: frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997). SENTRY study group (North America) Diagn Microbiol Infect Dis 34 1999 65 72
5. P.H. Summanen, D.A. Talan, and C. Strong Bacteriology of skin and soft-tissue infections: comparison of infections in intravenous drug users and individuals with no history of intravenous drug use Clin Infect Dis 20 Suppl. 2 1995 279 282
6. M. Raghavan, and P.K. Linden Newer treatment options for skin and soft tissue infections Drugs 64 2004 1621 1642
7. S.J. Martin, and D.G. Zeigler The use of fluoroquinolones in the treatment of skin infections Expert Opin Pharmacother 5 2004 237 246
8. H.B. Fung, J.Y. Chang, and S. Kuczynski A practical guide to the treatment of complicated skin and soft tissue infections Drugs 63 2003 1459 1480
9. D.R. Graham, D.A. Talan, and R.L. Nichols Once-daily, high-dose levofloxacin versus ticarcillin-clavulanate alone or followed by amoxicillin-clavulanate for complicated skin and skin-structure infections: a randomized, open-label trial Clin Infect Dis 35 2002 381 389
10. B.A. Lipsky, B. Miller, and R. Schwartz Sparfloxacin versus ciprofloxacin for the treatment of community-acquired, complicated skin and skin-structure infections Clin Ther 21 1999 675 690
11. M. Muller, H. Stass, M. Brunner, J.G. Moller, E. Lackner, and H.G. Eichler Penetration of moxifloxacin into peripheral compartments in humans Antimicrob Agents Chemother 43 1999 2345 2349
12. K. Malathum, K.V. Singh, and B.E. Murray In vitro activity of moxifloxacin, a new 8-methoxyquinolone against Gram-positive bacteria Diagn Microbiol Infect Dis 35 1999 127 133
13. M.E. Jones, M.R. Visser, M. Klootwijk, P. Heisig, J. Verhoef, and F.J. Schmitz Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin and nonquinolones linezolid, quinupristin-dalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxacin resistant and susceptible Staphylococcus aureus strains Antimicrob Agents Chemother 43 1999 421 423
14. S. Esposito, S. Noviello, F. Ianniello, and A. Novelli In vitro activity of moxifloxacin compared to other fluoroquinolones against different erythromycin-resistant phenotypes of Group A beta-haemolytic streptococcus Chemotherapy 46 2000 23 27
15. R.J. Fass In vitro activity of Bay 12-8039, a new 8-methoxyquinolone Antimicrob Agents Chemother 41 1997 1818 1824
16. G. Ackermann, R. Schaumann, and B. Pless Comparative activity of moxifloxacin in vitro against obligately anaerobic bacteria Eur J Clin Microbiol Infect Dis 19 2000 228 232
17. E.J. Goldstein, D.M. Citron, M. Hudspeth, S. Hunt Gerardo, and C.V. Merriam In vitro activity of Bay 12-8039, a new 8-methoxyquinolone, compared to the activities of 11 other oral antimicrobial agents against 390 aerobic and anaerobic bacteria isolated from human and animal bite wound skin and soft tissue infections in humans Antimicrob Agents Chemother 41 1997 1552 1557
18. H. Stass, D. Kubitza, A. Halabi, and H. Delesen Pharmacokinetics of moxifloxacin, a novel 8-methoxy-quinolone, in patients with renal dysfunction Br J Clin Pharmacol 53 2002 232 237
19. Stass H, Kubitza D, von Bergmann K, Halabi A, Kuhlmann J, Sudhop T. No dose adjustment is needed for patients with hepatic impairment receiving oral moxifloxacin. In: 9th European Congress of Clinical Microbiology and Infectious Diseases; 1999; Berlin, Germany. Abstract P0771.
20. M.-K. Kim, and C.H. Nightingale The quinolones: pharmacokinetics and pharmacodynamics of the fluoroquinolones V.T. Andriole The quinolones 2000 Academic Press San Diego, CA 169 202
21. H. Stass, and D. Kubitza Profile of moxifloxacin drug interactions Clin Infect Dis 32 Suppl. 1 2001 47 50
22. J.X. Song, and J.T. Wassell Sample size for K 2 × 2 tables in equivalence studies using Cochran's statistic Control Clin Trials 24 2003 378 389
23. L.C. Parish, H.B. Routh, and B. Miskin Moxifloxacin versus cephalexin in the treatment of uncomplicated skin infections Int J Clin Pract 54 2000 497 503
24. P. Leal del Rosal, R. Martinez, and G. Fabian Efficacy and safety of moxifloxacin vs. cephalexin in the treatment of mild to moderate uncomplicated skin and soft tissue infections (uSSSI) [abstract] J Antimicrob Chemother 44 Suppl. A 1999 148
25. Leal del Rosal P, Fabian G, Vick-Fragoso R, et al. Efficacy and safety of moxifloxacin vs cephalexin (with or without metronidazole) in the treatment of mild to moderate uncomplicated skin and skin structures infections (uSSSI) [abstract 716]. In: Program and Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 September 26-29; San Francisco, CA, USA. p. 716.
26. M.J. DiNubile, and B.A. Lipsky Complicated infections of skin and skin structures: when the infection is more than skin deep J Antimicrob Chemother 53 Suppl. 2 2004 ii37 ii50
27. M.N. Swartz Cellulitis and subcutaneous tissue infections G.L. Mandell J.E. Bennett R. Dolin Principles and practice of infectious disease 5th ed. 2000 Churchill Livingstone New York, NY 1037 1053
28. R.T. Lewis Soft tissue infections World J Surg 22 1998 146 151
29. D.R. Guay Treatment of bacterial skin and skin structure infections Expert Opin Pharmacother 4 2003 1259 1275
30. I. Brook Microbiology of polymicrobial abscesses and implications for therapy J Antimicrob Chemother 50 2002 805 810
31. B.A. Lipsky Medical treatment of diabetic foot infections Clin Infect Dis 39 Suppl. 2 2004 S104 S114
32. T.M. Gerkin, F.E. Eckhauser, S.E. Raper, M.W. Mulholland, J.A. Knol, and M.A. Schork Are traditional prognostic criteria useful in pancreatic abscess? Pancreas 10 1995 331 337
33. M.A. Malangoni, J.D. Richardson, J.C. Shallcross, J.G. Seiler, and H.C. Polk Jr. Factors contributing to fatal outcome after treatment of pancreatic abscess Ann Surg 203 1986 605 613
34. J.A.A. Perez, J.J. Gonazalez, and R.F. Baldonedo Clinical course, treatment, and multivariate analysis of risk factors for pyogenic liver abscess Am J Surg 181 2001 177 186
35. A.S. Bansal, and P. Prabhakar Clinical aspects of pyogenic liver abscess: The University Hospital of the West Indies experience J Trop Med Hyg 91 1988 87 93
36. R.J. Howard Surgical infections S.I. Schwartz G.T. Shires F.C. Spencer J.M. Daly J.E. Fischer A.C. Galloway Principles of surgery 7th ed. 1999 McGraw-Hill New York, NY 123 153